Welcome to Beyond Journal Club, a new collaboration with any Jam group where we take landmark trials and put them into context.

Too often with Journal Club, it's easy to get lost in the details of an article, struggling to figure out the clinical relevance through the tsunami of P values,

confidence intervals, and long table ones.

So today we will try to go beyond our typical journal clubs and instead tell a story of how we got to where we are to really appreciate the clinical

question of the trial at hand and then get into what these findings mean for our patients.

I'm Dr. Shrejurevetti, an internist at Bathies or Deaconess Medical Center. I'm Dr. Shrejurvedi an internist at Bathurst Medical Center.

I'm Dr. Greg Katz, cardiologist at NYU.

And I'm Dr. Clement Lee, a senior editorial fellow at the New England Journal of Medicine, which is part of any jam group.

Yes, we are so excited to launch this new collaboration between core am and any jam group.

So today we are talking the Revive Trial which was published in the October 13th

2022 issue of the New England Journal of Medicine. It's a really relevant trial to me

because it lives at the intersection of two diseases that I see so frequently, heart failure

and coronary artery disease.

Revived asked a very simple question.

This putting stents into patients with severe coronary artery disease and a reduced

ejection fraction make them live longer or reduce heart failure hospitalizations?

This is a great question because I can't tell you the number of times I've taken care of patients with a new drop in injection fraction.

The knee jerk reflex is to send them for a quote unquote,

achemic evaluation. Go to the Cath lab, look at their coronary anatomy.

But you know now that we're bringing this up,

what's a thought behind this ischemic evaluation and why are we just cathing these patients

who aren't actually having myocardial infarctions and may not even be having angina.

...